<DOC>
	<DOCNO>NCT01428427</DOCNO>
	<brief_summary>MEK112111 dose-escalation , Phase IB , open-label , single-arm , multi-center study . The primary objective study determine recommend dose regimen orally administer MEK inhibitor GSK1120212 dose combination gemcitabine subject solid tumor .</brief_summary>
	<brief_title>Combination Study GSK1120212 With Gemcitabine Subjects With Solid Tumors</brief_title>
	<detailed_description>Subjects enrol use dose-escalation procedure initial cohort receive fraction GSK1120212 dose achieve dose limit toxicity previous study recommend dose gemcitabine . Escalation proceed maximum tolerated dos identify . These dos select base emerge safety data . Confirmation tolerability Recommended Phase II Dose ( RP2D ) explore approximately 12 subject . Subjects continue treatment treatment discontinuation criterion meet ( disease progression , intercurrent illness , adverse event consent withdrawal ) .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Capable give write informed consent , include compliance requirement restriction list consent form . Age 18 year old old able swallow oral medication . Performance Status score 0 1 accord Eastern Cooperative Oncology ( ECOG ) scale . Histologically cytologically confirm diagnosis solid tumor malignancy either relapse refractory , potentially responsive gemcitabine . Tumor Type criterion list protocol . Male subject must agree use one contraception method list protocol . A female subject eligible participate nonchildbearing potential define protocol postmenopausal define protocol . If childbearing potential , agree use protocol specify contraceptive method Adequate organ system function define protocol . Chemotherapy , radiotherapy , immunotherapy within 28 day ( 42 day prior nitrosoureas mitomycin C ) prior first dose GSK1120212 . Use investigational anticancer drug within 28 day five halflives , whichever short precede first dose GSK1120212 long minimum 14 day pass last dose prior investigational anticancer drug first dose GSK1120212 . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , dimethy sulfoxide ( DMSO ) , excipients ( See protocol ) Use prohibit medication ( define protocol ) current use anticoagulant ( e.g . warfarin , heparin , low molecular weight heparin ) therapeutic level . Low dose ( prophylactic ) anticoagulant permit provide subject 's prothrombin time ( PT ) partial thromboplastin time ( PTT ) meet entry criterion . Gastrointestinal disease predict interfere absorption oral drug . History retinal vein occlusion ( RVO ) central serous retinopathy . Visible retinal pathology assess ophthalmologic exam consider risk factor retinal vein thrombosis . Glaucoma diagnose within one month prior study day 1 . Intraocular pressure &gt; 21mm Hg measure tonography . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . Subjects previously treat condition asymptomatic corticosteroid least two month permit . Subjects permit receive enzyme induce antiepileptic drug ( EIAEDs ) . Unresolved toxicity great common terminology criterion adverse event ( CTCAE v4.0 ) grade 1 previous anticancer therapy . History acute coronary within past 24 week . QTc interval great equal 480 mili second ( msec ) . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . Pregnant lactate female . History hepatitis B C. NOTE : Subjects evidence clear hepatitis B infection permit [ Hepatitis B Surface Antigen ( HBsAg ) negative , antiHBsAg positive anti Hepatitis B core antigen ( HBc ) positive . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>GSK1120212</keyword>
</DOC>